Member Exclusive

CRISPR-Cas9 approach identifies new drug targets to aid cancer immunotherapy

A novel CRISPR-Cas9 screening method developed by a team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center (Boston, MA, USA) has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising class of cancer immunotherapeutics.

Go to the profile of Peter Brown
Aug 03, 2017

Please sign in or register for FREE to view this content

Register to MedChemNet – the medicinal chemistry network

MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet. Start the conversation...